Syed Mustafa, MD
Allergy & Immunology · Rochester, NYNPI 1619023223
Payments from drug & device makers
Across 988 payments — averaging $3693.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$963K
- Astrazeneca UK Limited$616K
- Takeda Pharmaceuticals U.S.A., Inc.$445K
- Shire North American Group Inc$370K
- AstraZeneca$338K
- Regeneron$284K
- plus $633K from 24 others
Across 15 payments — averaging $1055.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$14K
- Regeneron$2K
What the payments were for
- Consulting fees$161,59317%
- Speaking & faculty fees$717,26376%
- Travel & lodging$43,1085%
- Food & beverage$26,3273%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 82 | $963,102 |
| Astrazeneca UK Limited | 3 | $616,371 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $444,725 |
| Shire North American Group Inc | 5 | $369,673 |
| AstraZeneca | 237 | $338,037 |
| Regeneron | 122 | $284,366 |
| Sanofi | 129 | $186,347 |
| Regeneron Healthcare Solutions, Inc. | 101 | $121,820 |
| GSK | 91 | $120,655 |
| Genentech USA, Inc. | 108 | $107,217 |
| Aimmune Therapeutics, Inc. | 17 | $28,982 |
| Amgen | 13 | $12,351 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $12,185 |
| Cumberland Pharmaceuticals, Inc. | 2 | $8,790 |
| Novartis | 13 | $8,780 |
| Pfizer | 7 | $8,278 |
| Alk-abello, Inc | 5 | $5,800 |
| Kaleo, Inc. | 7 | $4,671 |
| Pharming Healthcare, Inc. | 2 | $2,764 |
| Aquestive Therapeutics, Inc. | 2 | $2,196 |
| Sanofi US Services Inc. | 1 | $831 |
| Grifols USA, LLC | 4 | $322 |
| Shockwave Medical, Inc | 1 | $174 |
| Galderma Laboratories, L.p. | 2 | $121 |
| Optinose US, Inc. | 1 | $119 |
| Astellas Pharma US Inc | 1 | $99 |
| Johnson & Johnson | 3 | $82 |
| Scpharmaceuticals Inc. | 2 | $75 |
| Boehringer Ingelheim | 1 | $18 |
| USWM, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$330,339
- XOLAIR$94,121
- Hizentra$91,336
- NUCALA$90,080
- TEZSPIRE$76,506
- Privigen$53,488
- FASENRA$44,428
- AIRSUPRA$40,146
- PALFORZIA$23,658
- TRELEGY ELLIPTA$20,831
- NEFFY$12,096
- EVUSHELD$8,905
- AUVI-Q$4,550
- JOENJA$2,760
- LIBERVANT$2,135
- Odactra$1,000
- CUVITRU$760
- Xembify$224
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$174
- Xhance$119
How this compares
$3,648,964 in reported general payments places this provider in the 95th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 30 | $146,173 |
| Dupixent PenDupilumab | 27 | $108,891 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $92,227 |
| XolairOmalizumab | 32 | $80,868 |
| HyqviaIgg/Hyaluronidase,recombinant | 12 | $48,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $25,386 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,515 |
| DuleraMometasone/Formoterol | 14 | $4,730 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,449 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,071 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,777 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $1,228 |
| Ipratropium Bromide | 25 | $572 |
| Azelastine Hcl | 31 | $550 |
| Montelukast Sodium | 35 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $338,037 | $149,62146 claims |
| CSL BehringHizentra | $963,102 | $92,22713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $444,725 | $48,84012 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $120,655 | $33,90153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Rochester
- Peter DeaneRochester$3.7M
- John CondemiRochester$163K
- Richard LooneyRochester$117K
- Carolina MarcusRochester$78K
- Theresa BingemannRochester$47K
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$980K
- Mili ShumWest Harrison$924K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.